MarketCap
Facebook
X
TelegramAnnual report 2021
added 12-23-2023
Neovasc Total Assets 2011-2026 | NVCN
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Neovasc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 66.2 M | 17.9 M | 10.1 M | 13.3 M | 23.5 M | 98.8 M | 61.2 M | 20.4 M | 6.99 M | 8.84 M | 6.17 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 98.8 M | 6.17 M | 30.3 M |
Quarterly Total Assets Neovasc
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 66.2 M | - | - | - | 17.9 M | - | - | - | 10.1 M | - | - | - | 13.3 M | - | - | - | 23.5 M | - | - | - | 98.8 M | - | - | - | 61.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 98.8 M | 10.1 M | 41.6 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Electromed
ELMD
|
53.8 M | $ 25.1 | - | $ 212 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Helius Medical Technologies
HSDT
|
7.69 M | $ 1.98 | - | $ 1.2 M | USA |
 |
AdaptHealth Corp.
AHCO
|
4.32 B | $ 13.08 | - | $ 1.77 B | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
IRIDEX Corporation
IRIX
|
29.2 M | $ 1.03 | - | $ 17.4 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
509 M | $ 14.64 | - | $ 343 M | USA |
 |
LivaNova PLC
LIVN
|
2.61 B | $ 58.92 | - | $ 3.21 B |  Britain |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
77.2 M | $ 3.31 | - | $ 124 M |  France |
 |
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | USA |
 |
Insulet Corporation
PODD
|
3.19 B | $ 160.02 | - | $ 11.3 B | USA |
 |
BioSig Technologies
BSGM
|
188 M | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
Sintx Technologies
SINT
|
9.51 M | $ 1.99 | - | $ 5.52 M | USA |
 |
ClearPoint Neuro
CLPT
|
97.7 M | $ 10.34 | - | $ 293 M | USA |
 |
Stryker Corporation
SYK
|
47.8 B | $ 315.13 | - | $ 120 B | USA |
 |
Tactile Systems Technology
TCMD
|
274 M | $ 22.5 | - | $ 515 M | USA |
 |
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | USA |
 |
TELA Bio
TELA
|
81.4 M | $ 0.86 | - | $ 40.4 M | USA |
 |
Cytosorbents Corporation
CTSO
|
44.2 M | $ 0.64 | - | $ 39.8 M | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
TransMedics Group
TMDX
|
1.07 B | $ 98.57 | - | $ 3.35 B | USA |
 |
Tandem Diabetes Care
TNDM
|
881 M | $ 18.16 | - | $ 1.24 B | USA |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |
 |
Varex Imaging Corporation
VREX
|
1.11 B | $ 11.03 | - | $ 457 M | USA |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Vivos Therapeutics
VVOS
|
25.2 M | $ 0.78 | - | $ 8.01 M | USA |
 |
Butterfly Network
BFLY
|
256 M | $ 4.92 | - | $ 1.04 B | USA |
 |
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
5.3 B | $ 87.79 | - | $ 11.9 B | USA |
 |
Delcath Systems
DCTH
|
124 M | $ 10.21 | - | $ 366 M | USA |
 |
CONMED Corporation
CNMD
|
2.33 B | $ 35.96 | - | $ 1.12 B | USA |
 |
Inspire Medical Systems
INSP
|
907 M | $ 53.41 | - | $ 1.57 B | USA |
 |
Integer Holdings Corporation
ITGR
|
3.41 B | $ 83.67 | - | $ 2.91 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
13.7 B | $ 81.22 | - | $ 47.5 B | USA |
 |
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | USA |